Journal of AdvancedMedical and Dental Sciences Research

Background:Acute exacerbation of chronic bronchitis (AECB) refers to a sudden worsening of symptoms in individuals with chronic bronchitis, which is characterized by inflammation and irritation of the bronchial tubes. The present study was conducted to evaluate effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis. Materials & Methods:80 patients with acute exacerbation of chronic bronchitis of both genderswere divided into 2 groups of 40 each. Group I received either gemifloxacin 320 mg once daily and group II received cefpodoxime 200 mg twice daily orally for 7 days. Clinical success rate at day 14 visit and the changes in clinical global impression (CGI) scales and incidence of adverse events (AEs) were recorded. Results: Group I had 22 males and 18 females and group II had 17 males and 23 females. The mean respiratory symptoms score in group I and II at baseline was 8.5 and 9.3, at first follow up was 7.9 and 8.2 and at second follow up was 6.8 and 7.2 respectively. The difference was significant (P< 0.05). Clinical cure was seen in 23 in group I and 21 in group II, clinical improvement was seen in 12 in group I and 13 in group II and treatment failure was seen in 5 in group I and 6 in group II. The difference was non- significant (P> 0.05). Conclusion: For the treatment of AECB, a 7-day course of gemifloxacin is similar to cefpodoxime in terms of safety and clinical efficacy.